1. 1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394-424. [
DOI:10.3322/caac.21492]
2. Miranda-Filho A, Pineros M, Ferlay J, Soerjomataram I, Monnereau A, Bray F. Epidemiological patterns of leukaemia in 184 countries: a population-based study. Lancet Haematol. 2018;5(1): e14-e24. [
DOI:10.1016/S2352-3026(17)30232-6]
3. Koohi F, Salehiniya H, Shamlou R, Eslami S, Ghojogh ZM, Kor Y, et al. Leukemia in Iran: Epidemiology and morphology trends. Asian Pac J Cancer Prev. 2015;16(17):7759-63. [
DOI:10.7314/APJCP.2015.16.17.7759]
4. Amoori N, Mirzaei M, Cheraghi M. Incidence of cancers in Kuzestan province of iran: trend from 2004 to 2008. Asian Pac J Cancer Prev. 2014;15(19):8345-9. [
DOI:10.7314/APJCP.2014.15.19.8345]
5. Ahmadi Z, Shariati AA, Fayazi S, Latifi M. The Association Between Lifestyle and Incidence of Leukemia in Adults in Ahvaz, Iran. J Chronic Dis Care. 2016;5(2). [
DOI:10.17795/jjcdc-32924]
6. Bain BJ. Leukaemia diagnosis: John Wiley & Sons; 2017. [
DOI:10.1002/9781119210511]
7. Faderl S, O'brien S, Pui CH, Stock W, Wetzler M, Hoelzer D, et al. Adult acute lymphoblastic leukemia: concepts and strategies. Cancer. 2010;116(5):1165-76. [
DOI:10.1002/cncr.24862]
8. Robak T. Acute lymphoblastic leukaemia in elderly patients: biological characteristics and therapeutic approaches. Drugs Aging. 2004;21(12):779-91. [
DOI:10.2165/00002512-200421120-00003]
9. Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature. 2000;408(6810):307-10. [
DOI:10.1038/35042675]
10. Karimian A, Ahmadi Y, Yousefi B. Multiple functions of p21 in cell cycle, apoptosis and transcriptional regulation after DNA damage. DNA repair (Amst). 2016;42:63-71. [
DOI:10.1016/j.dnarep.2016.04.008]
11. Dunna NR, Vure S, Sailaja K, Surekha D, Raghunadharao D, Rajappa S, et al. TP53 codon 72 polymorphism and risk of acute leukemia. Asian Pac J Cancer Prev. 2012;13(1):347-50. [
DOI:10.7314/APJCP.2012.13.1.349]
12. Kassam S, Meyer P, Corfield A, Mikuz G, Sergi C. Single nucleotide polymorphisms (SNPs): history, biotechnological outlook and practical applications. Current Pharmacogenomics. 2005;3(3):237-245. [
DOI:10.2174/1570160054864021]
13. Pim D, Banks L. p53 polymorphic variants at codon 72 exert different effects on cell cycle progression. Int J Cancer. 2004;108(2):196-9. [
DOI:10.1002/ijc.11548]
14. Basu S, Murphy ME. Genetic modifiers of the p53 pathway. Cold Spring Harb Perspect Med. 2016;6(4):a026302. [
DOI:10.1101/cshperspect.a026302]
15. Chedid M, Michieli P, Lengel C, Huppi K, Givol D. A single nucleotide substitution at codon 31 (Ser/Arg) defines a polymorphism in a highly conserved region of the p53-inducible gene WAF1/CIP1. Oncogene. 1994;9(10):3021-4.
16. Grochola LF, Zeron-Medina J, Meriaux S, Bond GL. Single-nucleotide polymorphisms in the p53 signaling pathway. Cold Spring Harb perspect Biol. 2010;2(5):a001032. [
DOI:10.1101/cshperspect.a001032]
17. Keshava C, Frye BL, Wolff MS, McCanlies EC, Weston A. Waf-1 (p21) and p53 polymorphisms in breast cancer. Cancer Epidemiol Biomarkers Prev. 2002;11(1):127-30.
18. Bond GL, Hu W, Bond EE, Robins H, Lutzker SG, Arva NC, et al. A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell. 2004;119(5):591-602. [
DOI:10.1016/j.cell.2004.11.022]
19. Zhang Z, Wang H, Li M, Agrawal S, Chen X, Zhang R. MDM2 is a negative regulator of p21WAF1/CIP1, independent of p53. The Journal of biological chemistry. 2004;279(16):16000-16006. [
DOI:10.1074/jbc.M312264200]
20. Ebid GT, Sedhom IA, El-Gammal MM, Moneer MM. MDM2 T309G has a synergistic effect with P21 ser31arg single nucleotide polymorphisms on the risk of acute myeloid leukemia. Prevention Asian Pac J Cancer Prev. 2012;13(9):4315-20. [
DOI:10.7314/APJCP.2012.13.9.4315]
21. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988;16(3):1215. [
DOI:10.1093/nar/16.3.1215]
22. Chen J, Zhu B, Chen J, Li Y. Genetic variations in MDM2 and P53 genes confer risk for adult acute lymphoblastic leukemia in a Chinese population. DNA Cell Biol. 2013;32(7):414-9. [
DOI:10.1089/dna.2012.1900]
23. Phang BH, Linn YC, Li H, Sabapathy K. MDM2 SNP309 G allele decreases risk but does not affect onset age or survival of Chinese leukaemia patients. Eur J Cancer. 2008;44(5):760-6. [
DOI:10.1016/j.ejca.2008.02.007]
24. Yan YL, Han F, Tan WM, Wu CP, Qin X. Association between the MDM2 T309G polymorphism and leukemia risk: a meta-analysis. Asian Pac J Cancer Prev. 2014;15(16):6767-72. [
DOI:10.7314/APJCP.2014.15.16.6767]
25. Schulz E, Kashofer K, Heitzer E, Mhatre KN, Speicher MR, Hoefler G, et al. Preexisting TP53 mutation in therapy-related acute myeloid leukemia. Ann Hematol. 2015;94(3):527-9. [
DOI:10.1007/s00277-014-2191-0]
26. Dunna NR, Vure S, Sailaja K, Surekha D, Raghunadharao D, Rajappa S, et al. TP53 codon 72 polymorphism and risk of acute leukemia. Asian Pac J Cancer Prev. 2012;13(1):347-50. [
DOI:10.7314/APJCP.2012.13.1.349]
27. Tian X, Dai S, Sun J, Jiang S, Jiang Y. Association between TP53 Arg72Pro polymorphism and leukemia risk: a meta-analysis of 14 case-control studies. Sci Rep. 2016;6:24097. [
DOI:10.1038/srep24097]
28. Birgander R, Själander A, Saha N, Spitsyn V, Beckman L, Beckman G. The Codon 31 Polymorphism of the p53-lnducible Gene p21 Shows Distinct Differences between Major Ethnic Groups. Hum Hered. 1996;46(3):148-54. [
DOI:10.1159/000154344]
29. Kawamura M, Ohnishi H, Guo S-X, Sheng XM, Minegishi M, Hanada R, et al. Alterations of the p53, p21, p16, p15 and RAS genes in childhood T-cell acute lymphoblastic leukemia. Leuk Res. 1999;23(2):115-26. [
DOI:10.1016/S0145-2126(98)00146-5]